Athera Biotechnologies
Athera Biotechnologies is a Stockholm-based, private pharmaceutical R&D company founded in 2005 that develops drug-based solutions for risk assessment and treatment of cardiovascular diseases, operating with a 1–10 person team.
- Company typePrivate
- Founded2005
- HeadquartersStockholm, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Athera Biotechnologies firmographics
Firmographics- Name
- Athera Biotechnologies
- Website
- https://athera.se
- Company type
- Private
- Founded year
- 2005
- Headcount range
- 1–10 employees
- Short description
- Athera Biotechnologies is a Stockholm-based, private pharmaceutical R&D company founded in 2005 that develops drug-based solutions for risk assessment and treatment of cardiovascular diseases, operating with a 1–10 person team.
- Ownership category
- akta.pro rank
Athera Biotechnologies industry classification
Industry- Product category
- Cardiovascular Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
Keywords
Where Athera Biotechnologies is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Markets served
Athera Biotechnologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Athera Biotechnologies product offering
Product offeringCore offering
Athera Biotechnologies researches and develops pharmaceutical solutions for risk assessment and treatment of cardiovascular diseases. The company is a small, privately held biotech firm (1-10 employees) founded in 2005 and based in Stockholm, Sweden, focused on biopharmaceutical development for cardiovascular indications. No specific named products, clinical assets, or commercial offerings are disclosed in the available source data, and the company's web presence at athera.se is currently a parked domain.
Differentiator
Problem solved
Functional benefit
Companies that use Athera Biotechnologies
Customer profileIdeal customer profiles1 record
Athera Biotechnologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Athera Biotechnologies competitors and assessment
Company assessmentDirect peers
- Amarin Corporation: Cardiovascular-focused commercial-stage company with Vascepa (icosapent ethyl) for cardiovascular risk reduction — comparable to Athera as a specialist cardiovascular risk-management company.
- Regeneron Pharmaceuticals: Major biopharma whose Repatha (evolocumab) is an anti-PCSK9 monoclonal antibody for cardiovascular disease — directly analogous to Athera's prior anti-PCSK9 antibody focus and a benchmark for the asset class Athera targeted.
- Silence Therapeutics: UK-based clinical-stage biotech developing RNAi therapeutics against cardiovascular targets including PCSK9, addressing lipid-driven cardiovascular risk with a modality that overlaps with Athera's cardiovascular strategy.
- Resverlogix: Clinical-stage biotech developing apabetalone for cardiovascular disease with a focus on inflammatory and epigenetic mechanisms — a directly comparable therapeutic approach in cardiovascular inflammation.
- Esperion Therapeutics: US-based pharma focused on oral lipid management therapies (Nexletol/Nexlizet) for cardiovascular risk reduction — directly comparable to Athera's cardiovascular risk-reduction positioning.
- Cardior Pharmaceuticals: Germany-based clinical-stage biotech developing RNA-based therapeutics for heart failure and cardiac disease, making it a directly comparable European cardiovascular-focused biotech peer.
- Kancera: Swedish clinical-stage biotech developing small-molecule therapeutics in cardiovascular and inflammation indications — a regional and therapeutic-area peer within the Nordic biotech ecosystem.
Broad incumbents
- AstraZeneca: Global pharma with a substantial cardiovascular franchise (e.g., Brilinta, Farxiga) and a documented history of acquiring cardiovascular biotechs and assets — relevant as a likely acquirer profile for dormant CV IP.
- Novartis: Major pharma with cardiovascular portfolio including Entresto and a track record of acquiring cardiovascular-focused biotechs (e.g., The Medicines Company), making it a credible acquirer for residual cardiovascular IP.
Emerging players
- Vicore Pharma: Swedish clinical-stage biotech with programs in cardiovascular and respiratory indications, providing a regional and emerging-player reference point within the Nordic biotech landscape where Athera historically operated.
Market position
Customer concentration
Athera Biotechnologies social profiles
Digital presenceAthera Biotechnologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Athera Biotechnologies leadership team
Management profileNumber of profiles
Profiles2 records
Athera Biotechnologies funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Athera Biotechnologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Athera Biotechnologies
What does Athera Biotechnologies do?
Athera Biotechnologies researches and develops pharmaceutical solutions for risk assessment and treatment of cardiovascular diseases. The company is a small, privately held biotech firm (1-10 employees) founded in 2005 and based in Stockholm, Sweden, focused on biopharmaceutical development for cardiovascular indications. No specific named products, clinical assets, or commercial offerings are disclosed in the available source data, and the company's web presence at athera.se is currently a parked domain.
Is Athera Biotechnologies a public or private company?
Athera Biotechnologies is a private company. It is classified as venture growth investor backed.
When was Athera Biotechnologies founded?
Athera Biotechnologies was founded in 2005. It employs 1 to 10 people.
Where is Athera Biotechnologies based?
Athera Biotechnologies is headquartered in Stockholm, Sweden, in the Europe region.
Who are Athera Biotechnologies's main competitors?
Direct peers on record are Amarin Corporation, Regeneron Pharmaceuticals, Silence Therapeutics, Resverlogix, Esperion Therapeutics, Cardior Pharmaceuticals and Kancera. Broad incumbents are AstraZeneca and Novartis. Vicore Pharma is listed as an emerging player.
Does Athera Biotechnologies have an API?
No public API is recorded for Athera Biotechnologies.
What industry is Athera Biotechnologies in?
Athera Biotechnologies's product category is Cardiovascular Therapeutics. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.